Oliver G Ottmann

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Germany. Electronic address:

View Article and Find Full Text PDF

February 2017

Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.

Authors:

Sarah Oelsner Juliane Wagner Miriam E Friede Verena Pfirrmann Sabrina Genßler Eva Rettinger Christian J Buchholz Heike Pfeifer Ralf Schubert Oliver G Ottmann Evelyn Ullrich Peter Bader Winfried S Wels

Int J Cancer 2016 10 11;139(8):1799-809. Epub 2016 Jun 11.

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.

View Article and Find Full Text PDF

October 2016

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.

Blood 2016 08 27;128(6):774-82. Epub 2016 Apr 27.

Institute of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, United Kingdom.

View Article and Find Full Text PDF

August 2016

CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.

Authors:

Annette Romanski Christoph Uherek Gesine Bug Erhard Seifried Hans Klingemann Winfried S Wels Oliver G Ottmann Torsten Tonn

J Cell Mol Med 2016 07 23;20(7):1287-94. Epub 2016 Mar 23.

Institute for Transfusion Medicine and Immunohematology, J.W. Goethe University Frankfurt/Main, Red Cross Blood Donor Service Baden-Württemberg-Hessen, Dresden, Germany.

View Article and Find Full Text PDF

July 2016

Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients.

Authors:

Tina Vetter Andreas Borowski Andreas Wohlmann Nilabh Ranjan Michael Kuepper Susanne Badura Oliver G Ottmann Karlheinz Friedrich

Leuk Res 2016 Jan 22;40:38-43. Epub 2015 Oct 22.

Jena University Hospital, Institute of Biochemistry II, Jena, Germany. Electronic address:

View Article and Find Full Text PDF

January 2016

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

Authors:

Gabriela M Baerlocher Elisabeth Oppliger Leibundgut Oliver G Ottmann Gary Spitzer Olatoyosi Odenike Michael A McDevitt Alexander Röth Michael Daskalakis Bart Burington Monic Stuart David S Snyder

N Engl J Med 2015 Sep;373(10):920-8

From the Department of Hematology, University Hospital of Bern and University of Bern, Bern, Switzerland (G.M.B., E.O.L., M.D.); the Department of Hematology, School of Medicine, Cardiff University, Cardiff, United Kingdom (O.G.O.); Upstate Oncology Associates, Greenville, SC (G.S.); the Section of Hematology and Oncology, University of Chicago, Chicago (O.O.); the Divisions of Hematologic Malignancies and Hematology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore (M.A.M.); the Department of Hematology, University Hospital Essen, Essen, Germany (A.R.); and Geron, Menlo Park (B.B., M.S.), and the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Gehr Family Center for Leukemia Research, Duarte (D.S.S.) - both in California.

View Article and Find Full Text PDF

September 2015

Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.

Authors:

Ruth Seggewiss-Bernhardt Ralf C Bargou Yeow Tee Goh A Keith Stewart Andrew Spencer Adrian Alegre Joan Bladé Oliver G Ottmann Cristina Fernandez-Ibarra Hong Lu Scott Pain Mikhail Akimov Swaminathan Padmanabhan Iyer

Cancer 2015 Jul 24;121(13):2185-92. Epub 2015 Mar 24.

Department of Hematology, Houston Methodist Cancer Center, Houston, Texas, USA.

View Article and Find Full Text PDF

July 2015

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

Authors:

Hartmut Döhner Michael Lübbert Walter Fiedler Loic Fouillard Alf Haaland Joseph M Brandwein Stephane Lepretre Oumedaly Reman Pascal Turlure Oliver G Ottmann Carsten Müller-Tidow Alwin Krämer Emmanuel Raffoux Konstanze Döhner Richard F Schlenk Florian Voss Tillmann Taube Holger Fritsch Johan Maertens

Blood 2014 Aug 8;124(9):1426-33. Epub 2014 Jul 8.

University Hospital Gasthuisberg Leuven, Leuven, Belgium.

View Article and Find Full Text PDF

August 2014

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.

Authors:

Elias Jabbour Oliver G Ottmann Michael Deininger Andreas Hochhaus

Haematologica 2014 Jan;99(1):7-18

View Article and Find Full Text PDF

January 2014

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

Authors:

Susanne Badura Tamara Tesanovic Heike Pfeifer Sylvia Wystub Bart A Nijmeijer Marcus Liebermann J H Frederik Falkenburg Martin Ruthardt Oliver G Ottmann

PLoS One 2013 14;8(11):e80070. Epub 2013 Nov 14.

Department of Medicine, Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany.

View Article and Find Full Text PDF

August 2014

Treatment of patients with advanced cancer with the natural killer cell line NK-92.

Authors:

Torsten Tonn Dirk Schwabe Hans G Klingemann Sven Becker Ruth Esser Ulrike Koehl Meinolf Suttorp Erhard Seifried Oliver G Ottmann Gesine Bug

Cytotherapy 2013 Dec 1;15(12):1563-70. Epub 2013 Oct 1.

Institute for Transfusion Medicine and Immunohematology, Goethe University Hospital, Frankfurt am Main, Germany; German Red Cross Blood Donation Service, Baden-Württemberg-Hessen, Germany. Electronic address:

View Article and Find Full Text PDF

December 2013